The famous preparation gualou-guizhi decotion(GLGZD) is good for the recovery of illness after stroke happening in clinical practice. In order to illustrate the material foundation of neuroprotection and their mechanism of compatibility, our research intends to study it from both in vivo and in vitro models. Firstly, a qualitative analytical method of HPLC-DAD-Q-TOF-MS/MS was developed for identification of multi-constituents and an UPLC-QqQ-MS/MS analytical method was developed for simultaneously determining multi-constituents in GLGZD and its different herbal fomulation compatibility groups, and then all groups’ neuroprotective cause by excitatory toxicity of glutamate or oxidative stress were further evaluated by cell microelectronics impedance technology. As a result, studing the material foundation of neuroprotection and their mechanism of compatibility in vitro is by combining above-mentioned qualitative, quantitative and neuroprotective results. Secondly, a MD-2DLC-Q-TOF/MS method was developed for researching pharmacochemistry and cerebrospinal fluid-chemistry in MCAO model rat. On this foundation, an UPLC-QqQ-MS/MS analytical method was developed to determining active marker in GLGZD and further applied to pharmacokinetics after oral administration to rats. The changes of different pharmacokinetic parameters between GLGZD and its ingredient herbals were studied and would further illustrate the material foundation of neuroprotection and their mechanism of compatibility in vivo.
经方栝楼桂枝汤临床上用于脑卒中后康复有独特疗效,为了阐明栝楼桂枝汤神经保护的药效物质及其配伍机理,本研究从体内外两方面进行研究,首先,拟采用HPLC-DAD-Q-TOF-MS/MS和UPLC-QqQ-MS/MS联用技术,定性与定量探讨复方君、臣、佐、使不同配伍模式下物质基础的变化,结合细胞微电子阻抗技术实时监测分析不同配伍模式下复方对兴奋性毒性/氧化应激损伤神经保护作用的差异,通过“质”、“量”、“药效”相结合分析栝楼桂枝汤神经保护作用的药效物质及体外配伍机理。其次,拟采用MD-2DLC-Q-TOF/MS联用技术,定性分析栝楼桂枝汤配伍前后大脑中动脉阻塞MCAO模型大鼠复方体内血清/脑脊液药物化学组分,阐明复方血/脑中神经保护的移行成分;并在此基础上,选择活性标志物成分,采用UPLC-QqQ-MS/MS技术分析神经保护移行成分配伍前后药代动力学参数的变化,阐明复方药效物质体内配伍机理。
经方栝楼桂枝汤,出自《金匮要略》,药方由6味中药组成:天花粉,桂枝,白芍,甘草,生姜和大枣。经方栝楼桂枝汤临床上用于脑卒中后康复有独特疗效,为了阐明栝楼桂枝汤神经保护的药效物质及其配伍机理,本研究从药效物质基础研究和体内外配伍两方面进行研究,首先,拟采用HPLC-DAD-Q-TOF-MS/MS.和UPLC-QqQ-MS/MS联用技术,定性与定量探讨复方君、臣、佐、使不同配伍模式下物质基础的变化,共鉴定化学成分106个,并对21种氨基酸和41种栝楼桂枝汤主要成分进行定量分析;利用HSA和细胞微电子阻抗技术实时监测分析H2O2、谷氨酸诱导的神经损伤保护药效物质,HSA共筛选23种活性成分,细胞微电子阻抗技术分析筛选了栝楼桂枝汤中33种活性成分,通过“质”、“量”、“药效”相结合分析栝楼桂枝汤神经保护作用的药效物质及体外配伍机理。其次,采用LC-Q-TOF/MS联用技术,定性分析栝楼桂枝汤给药后正常大鼠和动脉阻塞MCAO模型大鼠复方体内血清药物化学和脑脊液化学组分,分析了42种入血原形成分及11种入脑、脑脊液化学成分,阐明复方血/脑中神经保护的移行成分,并在此基础上,选择活性标志物成分11个,采用UPLC-QqQ-MS/MS技术分析其药时曲线及药动学参数,并进一步针对关键神经保护移行成分芍药苷、甘草苷、甘草酸配伍前后药代动力学参数的变化,发现复方中3个活性成分的AUC和Tmax与单方或者单体相比有明显的升高,初步阐明复方药效物质体内配伍机理。
{{i.achievement_title}}
数据更新时间:2023-05-31
病毒性脑炎患儿脑电图、神经功能、免疫功能及相关因子水平检测与意义
EBPR工艺运行效果的主要影响因素及研究现状
妊娠对雌性大鼠冷防御性肩胛间区棕色脂肪组织产热的影响及其机制
神经退行性疾病发病机制的研究进展
基于限流级差配合的城市配电网高选择性继电保护方案
基于炎症反应-神经受损网络研究栝楼桂枝汤治疗缺血性脑卒中的药效物质及作用机制
栝楼桂枝汤对缺血性脑卒中后神经元-小胶质细胞crosstalk的调控机制研究
栝楼桂枝汤调控miR-155抑制缺血脑卒中后炎症反应的机制研究
基于生理药动学模型探讨丹参川芎对药保护MIRI的药效物质及配伍机制